Bridge to acquisition

First generation gamma secretase inhibitors didn't work in Alzheimer's disease, but Satori Pharmaceuticals Inc. is betting that its more selective gamma secretase modulator will not have the toxicity of previous compounds.

Last week, Satori raised $15 million in convertible debt from its venture investors. The expectation is the bridge financing will get the biotech to an IND for its lead gamma secretase modulator (GSM) by YE12 or early 2013, board member Chris Ehrlich of InterWest Partners told BioCentury...